随着最近批准的几种新疗法，转移性尿路上皮癌 (mUC) 的全球治疗格局正在不断发展。为了做出明智的治疗决策，需要了解治疗模式以及医生如何确定铂类治疗的资格状态。本研究调查了医生目前的一线 (1L) 化疗方法、治疗模式以及在现实临床实践中对 mUC 患者铂类治疗资格的评估。数据来源于 Adelphi mUC 疾病特定计划™，这是一项大型、独立、跨国、横断面调查，调查对象为医生及其在真实临床环境中咨询的 mUC 患者，该调查于 2020 年 11 月至 2021 年 4 月在法国、德国、意大利、西班牙和英国进行。为接下来的 8 名连续咨询患者（≤3 名 1L、≤2 名二线和 ≤3 名三线）填写记录表，这些患者经医生确认诊断为 mUC，报告人口统计数据、临床特征、铂类药物资格总体而言，232 名医生为 1922 名患者提供了数据。肾功能损害（72%）、东部肿瘤合作组的表现状态（59%）和年龄（38%）是医生用来确定铂类化疗资格的最常报告的标准。 1L 时，82% 的患者接受铂类化疗（顺铂，51%；卡铂，31%），10% 接受免疫检查点抑制剂 (ICI) 治疗。在二线治疗中，12% 接受铂类化疗，63% 接受 ICI 治疗，21% 接受非铂类化疗。在三线治疗中，4% 的患者接受了铂类化疗，41% 的患者仅接受了最佳支持治疗，36% 的患者接受了其他非铂类化疗。 这项真实世界研究的结果表明，根据欧洲指南，大多数患者接受了铂类化疗。 mUC 患者接受标准护理 1L 铂类化疗，ICIs 的使用受到限制。未来的研究应评估医生对确定铂类资格状态的看法如何随着更新的指南建议和 mUC 新治疗方案的引入而演变。版权所有 © 2023 作者。由爱思唯尔公司出版。保留所有权利。

The global treatment landscape for metastatic urothelial cancer (mUC) is evolving, with the recent approval of several new therapeutics. To enable informed treatment decisions, a need exists to understand both treatment patterns and how physicians determine platinum-based treatment eligibility status. This study investigated physicians' current approaches to first-line (1L) chemotherapy, treatment patterns, and assessment of platinum-based treatment eligibility of patients with mUC in real-world clinical practice.Data were derived from the Adelphi mUC Disease Specific Programme™, a large, independent, multinational, cross-sectional survey of physicians and their consulting patients with mUC presenting in a real-world clinical setting, conducted in France, Germany, Italy, Spain, and the United Kingdom between November 2020 and April 2021. Physicians completed record forms for their next 8 consecutively consulting patients (≤3 1L, ≤2 second-line, and ≤3 third-line) with a physician-confirmed diagnosis of mUC, reporting data on demographics, clinical characteristics, eligibility for platinum-based chemotherapy, and treatments received.Overall, 232 physicians provided data for 1922 patients. Renal function impairment (72%), Eastern Cooperative Oncology Group performance status (59%), and age (38%) were the most commonly reported criteria physicians used to determine eligibility for platinum-based chemotherapy. At 1L, 82% of patients received platinum-based chemotherapy (cisplatin, 51%; carboplatin, 31%) and 10% received immune checkpoint inhibitor (ICI) therapy. At second-line, 12% received platinum-based chemotherapy, 63% ICI therapy, and 21% non-platinum-based chemotherapy. At third-line, 4% received platinum-based chemotherapy, 41% best supportive care only, and 36% other non-platinum-based chemotherapy.The results of this real-world study indicate that in accordance with European guidelines, the majority of patients with mUC received standard-of-care 1L platinum-based chemotherapy and use of ICIs was limited. Future research should assess how physicians' perceptions toward determining platinum eligibility status evolve with newer guideline recommendations and the introduction of new therapy options for mUC.Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.